AbbVie (NYSE:ABBV) Releases Q3 2026 Earnings Guidance

Key Points

• AbbVie lowered its third-quarter 2026 adjusted EPS guidance to $3.73–$3.77, below the analyst consensus estimate of approximately $3.85. Full-year adjusted EPS guidance was also reduced to $13.76–$13.96 from $13.87–$14.07, partly due to $216 million in acquired in-process R&D and milestone expenses.
• Analysts remain broadly positive, with AbbVie receiving a consensus “Moderate Buy” rating and an average price target of $272.39. Shares opened at $265.93 and were up 1.2%, near their 12-month high.
• AbbVie declared a quarterly dividend of $1.73 per share, equivalent to $6.92 annually and a 2.6% yield, payable November 16 to shareholders of record October 15.

AbbVie (NYSE:ABBV - Get Free Report) issued an update on its third quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 3.730-3.770 for the period, compared to the consensus EPS estimate of 3.850. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. HSBC upped their target price on AbbVie from $300.00 to $315.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. Canaccord Genuity Group increased their target price on AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Oppenheimer lifted their price target on AbbVie from $244.00 to $258.00 and gave the stock a "neutral" rating in a research report on Monday, August 3rd. Royal Bank Of Canada upped their price target on AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a report on Friday, July 10th. Finally, Barclays increased their price objective on AbbVie from $275.00 to $300.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of "Moderate Buy" and an average price target of $272.39.

AbbVie Stock Up 1.2%

Shares of AbbVie stock opened at $265.93 on Tuesday. The stock has a market capitalization of $469.84 billion, a P/E ratio of 75.12, a price-to-earnings-growth ratio of 1.19 and a beta of 0.24. The company has a 50-day simple moving average of $258.05 and a 200 day simple moving average of $235.01. AbbVie has a 12-month low of $190.75 and a 12-month high of $269.39.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts anticipate that AbbVie will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.6%. The ex-dividend date is Thursday, October 15th. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company's stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and partner Genmab reported positive Phase 3 results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma. The treatment produced a statistically significant and clinically meaningful improvement in progression-free survival versus R-CHOP alone, potentially expanding epcoritamab into frontline treatment and supporting future regulatory filings. AbbVie and Genmab lymphoma trial announcement
• Positive Sentiment: The lymphoma result strengthens AbbVie’s bispecific-antibody strategy and could add a new growth opportunity as the company seeks to diversify beyond its mature immunology portfolio. Reports indicated the combination reduced the risk of progression or death by approximately 51%. AbbVie lymphoma trial risk reduction report
• Positive Sentiment: The FDA approved AbbVie’s new Parkinson’s treatment, described as the first approved selective D1/D5 drug, adding another commercial product to the company’s neuroscience franchise. AbbVie Parkinson’s treatment approval
• Neutral Sentiment: AbbVie joined a federal 340B rebate pilot program ahead of its planned 2027 launch. The impact is uncertain, but the program could influence future pricing and reimbursement for participating medicines. AbbVie 340B rebate pilot
• Negative Sentiment: AbbVie lowered third-quarter 2026 adjusted EPS guidance to $3.73–$3.77, below the approximately $3.85 analyst consensus, after including $216 million of acquired in-process research and development and milestone expenses. Full-year adjusted EPS guidance was reduced to $13.76–$13.96 from $13.87–$14.07. AbbVie updated earnings guidance

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.